With a history that spans almost a century, C.A.PAPAELLINAS Group has become a market leader in the sectors in which it operates. These include the promotion and distribution of pharmaceuticals, pharmacy products, food supplements, cosmetics and consumer goods, as well as a strong network of retail stores and integrated distribution services. In the broad context of its business operations, the Group has developed robust partnerships with leading multinational companies, as their exclusive representative in the Cypriot market.
Through its strong relationship of trust with the Cypriot consumer, the Group implements the strategy of its methodical expansion, while it paves new roads of quality and reliability, having already been established as the leading group of health and beauty products in Cyprus.
With its timeless mission of making more and more people live and feel better, C.A.PAPAELLINAS Group believes that the concepts of growth and development can only gain meaning when combined with business ethics. It considers sustainability as the only realistic approach to new challenges, focusing all its efforts on ensuring social prosperity, economic growth and environmental protection.
FROM 1930 TO THE PRESENT DAY
The business activity of C.A.PAPAELLINAS Group begins just before 1930 with the import of pharmaceutical products in Cyprus. The year 1931 will be a milestone in the company’s history, as it marks the beginning of its collaboration with the world leader Sandoz Chemicals (now Novartis). This will bring more collaborations with other major companies in the pharmaceutical industry, such as Organon Pharmaceuticals. 100 years later, pharmaceutical products remain at the centre of the mission and operations of the Group. Through an integrated distribution network, the Group provides in the Cypriot market pharmaceuticals, pharmacy products and food supplements, for the improvement of health and well-being in every stage of life.
KEY PARTNERSHIPS WITH LEADING BRANDS
In the Pharmacy Product Sector, the Group represents multinational companies such as Haleon and Perrigo with non-prescription pharmaceutical products that dominate the Cypriot market. These include the following brands: Panadol, Solpadeine, Physiomer, Otrivin, Voltaren Gel, Sensodyne, etc.
Furthermore, the Group maintains a number of significant collaborations with leading companies in the Food Supplement Sector (Lanes, Centrum, Femarelle, Superfoods, Optima, My Elements, Mastiha Art of Nature) and in Pharmacy Cosmetics (NUXE and Bio-Oil).
TRAINED STAFF
The Pharmaceutical and Pharmacy Product Sectors are supported by the scientific information and promotion departments, as well as the medical and compliance departments. All departments are recruited by highly qualified personnel who participate in ongoing training programmes and provide services on Pharmacovigilance, Quality and Safety Regulation, and Medicine Registration. These services assist the Group in ensuring compliance with both the European and local regulations governing the promotion of Pharmaceuticals in Cyprus. The Group, as the local representative of the brands it imports, is able to provide all necessary services to Marketing Authorisation Holders, ensuring the products’ placement in the Cypriot market, for both the medical community and the patients.
100% MARKET SHARE
For more than two decades, PharmacyLine, a member of the Group, is responsible for the storage, distribution and repacking of the pharmaceutical products of the brands represented by the Group, as well as other products, as a 3PL service provider.
In the context of pursuing the Group’s mission, PharmacyLine aims to supply pharmaceutical products to pharmacies and public health institutions with a focus on speed, safety and service, in accordance with the highest quality standards.
With a 100% market share in the Cypriot market, more than 55,000 deliveries of refrigerated and non-refrigerated pharmaceutical products are carried out annually, with a Perfect Order Rate of 99.96%.
STRICT STANDARDS
The continuous improvement of operational processes and the use of technology aim at providing competitive services, in terms of both quality and cost.
Supporting the Group’s strategy in the Pharmaceutical and Pharmacy Product Sectors, and at the same time being prepared for any possible partnership, PharmacyLine is proceeding with the expansion of its warehouse facilities within 2024, increasing its storage capacity by more than 1,500 pallet locations.
PharmacyLine has a dedicated quality assurance department (GxP) which prescribes and monitors through SOPs (Standard Operating Procedures) the entire range of storage and distribution operations. These operations are regularly audited by government authorities and the Group’s pharmaceutical suppliers, with excellent results.
PharmacyLine is certified to the ISO 9001:2015 standard for Quality Management Systems and the ISO 14001:2015 standard for Environmental Management Systems, while the ISO 45001:2018 Occupational Health and Safety Management Systems certification is in progress.
STRONG PRESENCE IN THE MARKET
The introduction of the General Healthcare System (GHS) in the Cypriot healthcare sector has reinforced the Cypriot pharmaceutical market, while major challenges are emerging in the entire spectrum of activity of the Group’s Pharmaceutical Department.
In the Prescription Medicines Sector, the market has been completely shaped by the increase in the number of Health Professionals required for the successful provision of information on medicines as well as their promotion, while the visit time has been significantly reduced. The Group has fully responded to this challenge by increasing its personnel, reinforcing its medical associates both scientifically and in terms of communication, as well as by applying modern digital methods. These methods can provide effective organisation and communication support to medical representatives, like the VEEVA CRM Platform, and extend the spectrum of their activities beyond the in-person medical visits, such as webinars, Rep email marketing, etc.
In the Sector of Specialised Innovative Medicines (INN-innovative medicines), the challenges are even greater as we are going through the transitional stage of the full implementation of the GHS for this category of medication. Here also the excellent collaboration of the specialised personnel with the respective departments of the Companies represented by C.A.PAPAELLINAS Group guarantees the supply of these Medicines to the Cypriot market, either through the submission of applications or through performance-based Managed Entry Agreements with the HIO, under the protocols established by the organisation.
In the Non-Prescription Medicines Sector, with the implementation of the GHS, the market has expanded significantly since numerous non-prescription medicines are not provided by the GHS. The significant diversification of Pharmacy operations, due to the increased patient flow in Private Pharmacies, has generated the need to upgrade the targeted category placement within pharmacies in order to ensure that people’s individual needs are being fully covered. At the same time our Group, recognising the Pharmacists’ insufficient time, has implemented a B2B platform which gives them the possibility to be immediately informed about products and place online orders for any product of the Group. The constant upgrading of our Pharmaceutical and Medical representatives’ education in terms of communication skills and scientific training, as well as the digital upgrading with the Coprime Platform that ensures the proper administration and promotion processes, are also of great importance for the Group.
A RICH PRODUCT PORTFOLIO
The well-diversified pharmaceutical product portfolio of the Group includes a multitude of medicines for chronic medical conditions, vaccines, but also specialised pharmaceutical products for rare diseases, oncological and hematological medicines, medicines for the central nervous system, etc. International companies that entrust their exclusive representation in Cyprus to the Pharmaceutical Sector of the Group are: Sanofi, Amgen, Servier, Ipsen, Teva, Advanz, Baxter, Celltrion Healthcare, Faes Farma, Fresenius, Galenica, ITF, Kyowa Kirin, Verisfield, and Vianex. Overall, the provision of the following services is also included: scientific information, response to medical questions, and negotiation of managed entry agreements for the introduction of innovative medicines in the GHS, with the aim of ensuring their availability and accessibility for the Cypriot patients under the protocols established by the Health Insurance Organisation (HIO). Furthermore, other major multinational companies, such as Novartis, are also represented in the Distribution Sector of the Group.
Management team of the Group
Chief Executive Officer: Christos Papaellinas
Senior General Manager – Pharma: Stelios Phinikarides
General Manager Pharmacy Brands: Andri Koukou
Senior Commercial Manager – Pharma: Alexia Nicolaidou
Contact details of the Group
Telephone: +357 2274174
Email: info@cap.com.cy
Address: 179 Yiannos Kranidiotis Ave., 2235 Latsia, Nicosia
UNLIMITED POTENTIAL
An important and timeless factor in the C.A.PAPAELLINAS Group’s success in the Pharmaceutical market, is the agreements of strategic importance that the Group has concluded with world-renowned multinational Pharmaceutical companies, gaining multifaceted and extensive experience. The Group strongly believes that, with the wide range of its services and its well-trained and scientifically qualified staff, is able to successfully undertake and develop any new strategic partnership. The Group’s core objective is to ensure access of all people to more and more Pharmaceutical and Pharmacy products in Cyprus. Products that relieve, heal and make more and more people live and feel better.
